Literature DB >> 21215704

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Sarat Chandarlapaty1, Ayana Sawai, Maurizio Scaltriti, Vanessa Rodrik-Outmezguine, Olivera Grbovic-Huezo, Violeta Serra, Pradip K Majumder, Jose Baselga, Neal Rosen.   

Abstract

Activation of the PI3K-AKT pathway in tumors is modulated by negative feedback, including mTORC1-mediated inhibition of upstream signaling. We now show that AKT inhibition induces the expression and phosphorylation of multiple receptor tyrosine kinases (RTKs). In a wide spectrum of tumor types, inhibition of AKT induces a conserved set of RTKs, including HER3, IGF-1R, and insulin receptor. This is in part due to mTORC1 inhibition and in part secondary to a FOXO-dependent activation of receptor expression. PI3K-AKT inhibitors relieve this feedback and activate RTK signaling; this may attenuate their antitumor activity. Consistent with this model, we find that, in tumors in which AKT suppresses HER3 expression, combined inhibition of AKT and HER kinase activity is more effective than either alone. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21215704      PMCID: PMC3025058          DOI: 10.1016/j.ccr.2010.10.031

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  35 in total

1.  Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.

Authors:  Deborah DeFeo-Jones; Stanley F Barnett; Sheng Fu; Paula J Hancock; Kathleen M Haskell; Karen R Leander; Elizabeth McAvoy; Ronald G Robinson; Mark E Duggan; Craig W Lindsley; Zhijian Zhao; Hans E Huber; Raymond E Jones
Journal:  Mol Cancer Ther       Date:  2005-02       Impact factor: 6.261

2.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

3.  Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

Authors:  Dhara N Amin; Natalia Sergina; Deepika Ahuja; Martin McMahon; Jimmy A Blair; Donghui Wang; Byron Hann; Kevin M Koch; Kevan M Shokat; Mark M Moasser
Journal:  Sci Transl Med       Date:  2010-01-27       Impact factor: 17.956

4.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Authors:  Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

5.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Authors:  Andrea D Basso; David B Solit; Pamela N Munster; Neal Rosen
Journal:  Oncogene       Date:  2002-02-14       Impact factor: 9.867

6.  A negative feedback signaling network underlies oncogene-induced senescence.

Authors:  Stéphanie Courtois-Cox; Sybil M Genther Williams; Elizabeth E Reczek; Bryan W Johnson; Lauren T McGillicuddy; Cory M Johannessen; Pablo E Hollstein; Mia MacCollin; Karen Cichowski
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

7.  ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.

Authors:  U Hermanto; C S Zong; L H Wang
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

8.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Authors:  F Michael Yakes; Wichai Chinratanalab; Christoph A Ritter; Walter King; Steven Seelig; Carlos L Arteaga
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

9.  Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Authors:  Elizabeth Buck; Alexandra Eyzaguirre; Maryland Rosenfeld-Franklin; Stuart Thomson; Mark Mulvihill; Sharon Barr; Eric Brown; Mathew O'Connor; Yan Yao; Jonathan Pachter; Mark Miglarese; David Epstein; Kenneth K Iwata; John D Haley; Neil W Gibson; Qun-Sheng Ji
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  Inhibitor hijacking of Akt activation.

Authors:  Tatsuya Okuzumi; Dorothea Fiedler; Chao Zhang; Daniel C Gray; Brian Aizenstein; Randy Hoffman; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2009-05-24       Impact factor: 15.040

View more
  469 in total

1.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Authors:  Vanessa S Rodrik-Outmezguine; Sarat Chandarlapaty; Nen C Pagano; Poulikos I Poulikakos; Maurizio Scaltriti; Elizabeth Moskatel; José Baselga; Sylvie Guichard; Neal Rosen
Journal:  Cancer Discov       Date:  2011-06-17       Impact factor: 39.397

2.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Authors:  Imran Ahmad; Rachana Patel; Lukram Babloo Singh; Colin Nixon; Morag Seywright; Robert J Barnetson; Valerie G Brunton; William J Muller; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice.

Authors:  Juyeon Park; Jimmy Zhang; Jianhua Qiu; Xiaoxia Zhu; Alexei Degterev; Eng H Lo; Michael J Whalen
Journal:  J Cereb Blood Flow Metab       Date:  2011-09-21       Impact factor: 6.200

4.  Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer.

Authors:  Yunfei Wen; Ying Wang; Anca Chelariu-Raicu; Elaine Stur; Yuan Liu; Sara Corvigno; Faith Bartsch; Lauren Redfern; Behrouz Zand; Yu Kang; Jinsong Liu; Keith Baggerly; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2020-07-31       Impact factor: 6.261

5.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Authors:  Hiromichi Ebi; Carlotta Costa; Anthony C Faber; Madhuri Nishtala; Hiroshi Kotani; Dejan Juric; Patricia Della Pelle; Youngchul Song; Seiji Yano; Mari Mino-Kenudson; Cyril H Benes; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-10       Impact factor: 11.205

6.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 7.  Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

Authors:  Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

Review 8.  Molecular pathways: HER3 targeted therapy.

Authors:  Kinisha Gala; Sarat Chandarlapaty
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

9.  Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.

Authors:  Sarat Chandarlapaty; Rita A Sakr; Dilip Giri; Sujata Patil; Adriana Heguy; Monica Morrow; Shanu Modi; Larry Norton; Neal Rosen; Clifford Hudis; Tari A King
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

Review 10.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.